197 related articles for article (PubMed ID: 8373731)
41. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
42. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: implications for gene therapy.
Skladanowski A; Larsen AK
Cancer Res; 1997 Mar; 57(5):818-23. PubMed ID: 9041178
[TBL] [Abstract][Full Text] [Related]
43. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562.
Ehinger M; Nilsson E; Persson AM; Olsson I; Gullberg U
Cell Growth Differ; 1995 Jan; 6(1):9-17. PubMed ID: 7718488
[TBL] [Abstract][Full Text] [Related]
44. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
45. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Shaulsky G; Goldfinger N; Rotter V
Cancer Res; 1991 Oct; 51(19):5232-7. PubMed ID: 1717142
[TBL] [Abstract][Full Text] [Related]
46. [Inhibitory effect of p53 with deletion of c-terminal 356 - 393 amino acids on malignant phenotype of human lung cancer cell line].
Wang H; Li JZ; Lai BT; Yang XH; Zhang CY; Yue WT; Zhan XP
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):527-30. PubMed ID: 14690553
[TBL] [Abstract][Full Text] [Related]
47. Friend virus induced murine erythroleukaemia: the p53 locus.
Johnson P; Benchimol S
Cancer Surv; 1992; 12():137-51. PubMed ID: 1638545
[TBL] [Abstract][Full Text] [Related]
48. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
49. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
Dolnikov A; Millington M; Sun LQ; Symonds G
Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
[TBL] [Abstract][Full Text] [Related]
50. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Huang Y; Tan M; Gosink M; Wang KK; Sun Y
Cancer Res; 2002 May; 62(10):2913-22. PubMed ID: 12019172
[TBL] [Abstract][Full Text] [Related]
51. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
52. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.
Lang D; Miknyoczki SJ; Huang L; Ruggeri BA
Oncogene; 1998 Mar; 16(12):1593-602. PubMed ID: 9569027
[TBL] [Abstract][Full Text] [Related]
53. Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens.
Christensen JG; Goldsworthy TL; Cattley RC
Mol Carcinog; 1999 Aug; 25(4):273-84. PubMed ID: 10449034
[TBL] [Abstract][Full Text] [Related]
54. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
55. DNA binding and selective gene induction by different forms of the p53 protein.
Mayelzadeh F; Martinez JD
Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840
[TBL] [Abstract][Full Text] [Related]
56. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
57. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.
Cheung AM; Hande MP; Jalali F; Tsao MS; Skinnider B; Hirao A; McPherson JP; Karaskova J; Suzuki A; Wakeham A; You-Ten A; Elia A; Squire J; Bristow R; Hakem R; Mak TW
Cancer Res; 2002 Nov; 62(21):6194-204. PubMed ID: 12414647
[TBL] [Abstract][Full Text] [Related]
58. A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes.
Yamato K; Yamamoto M; Hirano Y; Tsuchida N
Oncogene; 1995 Jul; 11(1):1-6. PubMed ID: 7624116
[TBL] [Abstract][Full Text] [Related]
59. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes.
Caelles C; Helmberg A; Karin M
Nature; 1994 Jul; 370(6486):220-3. PubMed ID: 8028670
[TBL] [Abstract][Full Text] [Related]
60. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.
Milner J; Medcalf EA
J Mol Biol; 1990 Dec; 216(3):481-4. PubMed ID: 2258922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
